Tags : lipid nanoparticle (LNP) technology

Novartis Expands its Cell Therapy Collaboration with Intellia Therapeutics for

Vartika Singh December 7, 2018

Shots: Intellia to receive $10M upfront, milestones and royalties on sales. Novartis to get rights to Intellia’s CRISPR/Cas9 technology for the development of ex-vivo cell therapy using ocular stem cells […]readmore

Tags : lipid nanoparticle (LNP) technology

Novartis Expands its Cell Therapy Collaboration with Intellia Therapeutics for

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : lipid nanoparticle (LNP) technology

Novartis Expands its Cell Therapy Collaboration with Intellia Therapeutics for

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company